Equicord

Menu

HorStem

Development

EquiCord has conducted an exhaustive research and development process to demonstrate the quality, safety, and efficacy of umbilical cord stem cells.

Clinical Development

Authorizing a product as a veterinary medicine requires conducting various clinical trials to ensure the safety and efficacy of the medicine.

At EquiCord we have conducted 7 clinical trials for marketing authorization and are currently developing 3 more trials.

Safety and efficacy of MSCs in equine OA

Preclinical

Proof of concept:

Safety of the intra-articular allogeneic use of equine umbilical cord mesenchymal stem cells in healthy horses

Phase I

  • Safety Study in Target Species: Single and Repeated Dose

*VICH GL9

  • Clinical trial Immunogenicity: Cellular and Humoral response

*VICH GL9

  • Clinical Study on Tumor Genesis

Phase II

Proof of concept:

Safety and efficacy investigation of intra-articular administration of selected doses of allogeneic umbilical cord stem cells in horses with degenerative joint disease

*VICH GL9

Phase III

  • Determination of the safety and efficacy of EUC-MSCs in the symptomatic treatment associated with degenerative joint disease (osteoarthritis) in horses under field conditions

*VICH GL9

  • Confirmation of the safety and efficacy of intra-articular administration of allogeneic umbilical cord mesenchymal stem cells in horses with degenerative disease

*VICH GL9

Phase IV

  • Long-term safety and efficacy study: two-year follow-up safety and efficacy study
  • Post-marketing survey study in 800 horses on the safety and efficacy of HorStem

*VICH GL9

Mechanism of action of MSCs

Clinical results

Clinical trials designed and conducted by our scientific team have shown that HorStem is effective in reducing lameness in horses with mild to moderate degenerative joint disease.

All our clinical trials have been carried out following the international regulations for the homogenization of clinical trials VICH GL9 and after authorization from the Spanish Agency for Medicines and Health Products (AEMPS).

72% of the treated horses reduced their degree of lameness to no lameness or inconsistent lameness

(≤ grade 1 according to the American Scale of Equine Veterinarians)

Likewise, long-term studies have shown that the effectiveness of HorStem is very long-lasting, showing that 83% of the animals did not relapse in their symptoms or need additional medication 12 months after the application of HorStem.

DISCOVER OUR TECHNOLOGY